Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agape ATP Corporation stock logo
ATPC
Agape ATP
$1.29
-0.4%
$1.32
$0.90
$2.93
$64.26M-0.981.23 million shs5,287 shs
DocGo Inc. stock logo
DCGO
DocGo
$1.39
-0.4%
$1.53
$1.23
$5.68
$135.47M0.97783,129 shs31,056 shs
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$3.01
+1.9%
$2.88
$1.37
$9.13
$113.20M1206,060 shs467 shs
Exagen Inc. stock logo
XGN
Exagen
$10.94
+3.5%
$9.21
$2.38
$11.17
$240.57M1.6226,607 shs111,551 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agape ATP Corporation stock logo
ATPC
Agape ATP
-0.08%0.00%-5.19%-3.03%-33.33%
DocGo Inc. stock logo
DCGO
DocGo
-4.79%-10.32%-15.76%-13.13%-58.51%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-4.53%-7.81%-3.28%-27.87%-61.69%
Exagen Inc. stock logo
XGN
Exagen
-1.95%+9.53%+6.77%+51.00%+254.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Agape ATP Corporation stock logo
ATPC
Agape ATP
$1.29
-0.4%
$1.32
$0.90
$2.93
$64.26M-0.981.23 million shs5,287 shs
DocGo Inc. stock logo
DCGO
DocGo
$1.39
-0.4%
$1.53
$1.23
$5.68
$135.47M0.97783,129 shs31,056 shs
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$3.01
+1.9%
$2.88
$1.37
$9.13
$113.20M1206,060 shs467 shs
Exagen Inc. stock logo
XGN
Exagen
$10.94
+3.5%
$9.21
$2.38
$11.17
$240.57M1.6226,607 shs111,551 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Agape ATP Corporation stock logo
ATPC
Agape ATP
-0.08%0.00%-5.19%-3.03%-33.33%
DocGo Inc. stock logo
DCGO
DocGo
-4.79%-10.32%-15.76%-13.13%-58.51%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-4.53%-7.81%-3.28%-27.87%-61.69%
Exagen Inc. stock logo
XGN
Exagen
-1.95%+9.53%+6.77%+51.00%+254.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Agape ATP Corporation stock logo
ATPC
Agape ATP
0.00
N/AN/AN/A
DocGo Inc. stock logo
DCGO
DocGo
2.40
Hold$3.24133.75% Upside
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
0.00
N/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
3.00
Buy$12.009.74% Upside

Current Analyst Ratings Breakdown

Latest ATPC, XGN, DCGO, and SERA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/11/2025
Exagen Inc. stock logo
XGN
Exagen
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$15.00
9/10/2025
Exagen Inc. stock logo
XGN
Exagen
B. Riley
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$15.00
8/21/2025
DocGo Inc. stock logo
DCGO
DocGo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetHold$1.45 ➝ $1.60
7/30/2025
Exagen Inc. stock logo
XGN
Exagen
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$10.00
7/30/2025
Exagen Inc. stock logo
XGN
Exagen
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$8.00 ➝ $11.00
7/30/2025
Exagen Inc. stock logo
XGN
Exagen
KeyCorp
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSector WeightOverweight$12.00
7/23/2025
Exagen Inc. stock logo
XGN
Exagen
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$12.00
(Data available from 9/26/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Agape ATP Corporation stock logo
ATPC
Agape ATP
$1.32M48.68N/AN/A$0.48 per share2.68
DocGo Inc. stock logo
DCGO
DocGo
$616.55M0.22$0.40 per share3.45$3.09 per share0.45
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
$80K1,414.98N/AN/A$1.40 per share2.15
Exagen Inc. stock logo
XGN
Exagen
$55.64M4.32N/AN/A$0.54 per share20.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Agape ATP Corporation stock logo
ATPC
Agape ATP
-$2.47M-$0.41N/AN/A-183.13%-20.32%-18.55%11/12/2025 (Estimated)
DocGo Inc. stock logo
DCGO
DocGo
$19.99M-$0.19N/A17.31N/A-4.20%-3.26%-2.24%11/6/2025 (Estimated)
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$32.90M-$0.85N/AN/AN/A-30,306.48%-45.86%-34.31%11/5/2025 (Estimated)
Exagen Inc. stock logo
XGN
Exagen
-$15.11M-$0.89N/AN/AN/A-28.85%-130.38%-34.69%11/11/2025 (Estimated)

Latest ATPC, XGN, DCGO, and SERA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Agape ATP Corporation stock logo
ATPC
Agape ATP
N/A-$0.01N/A-$0.01N/AN/A
8/7/2025Q2 2025
DocGo Inc. stock logo
DCGO
DocGo
-$0.06-$0.11-$0.05-$0.11$77.58 million$80.42 million
8/6/2025Q2 2025
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
-$0.21-$0.16+$0.05-$0.16$0.05 million$0.02 million
7/29/2025Q2 2025
Exagen Inc. stock logo
XGN
Exagen
-$0.18-$0.18N/A-$0.21$16.25 million$17.20 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Agape ATP Corporation stock logo
ATPC
Agape ATP
N/AN/AN/AN/AN/A
DocGo Inc. stock logo
DCGO
DocGo
N/AN/AN/AN/AN/A
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/AN/AN/AN/AN/A
Exagen Inc. stock logo
XGN
Exagen
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Agape ATP Corporation stock logo
ATPC
Agape ATP
N/A
20.36
20.33
DocGo Inc. stock logo
DCGO
DocGo
N/A
2.36
2.36
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
N/A
1.73
1.73
Exagen Inc. stock logo
XGN
Exagen
1.06
4.95
4.95

Institutional Ownership

CompanyInstitutional Ownership
Agape ATP Corporation stock logo
ATPC
Agape ATP
0.01%
DocGo Inc. stock logo
DCGO
DocGo
56.44%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
54.64%
Exagen Inc. stock logo
XGN
Exagen
75.25%

Insider Ownership

CompanyInsider Ownership
Agape ATP Corporation stock logo
ATPC
Agape ATP
9.67%
DocGo Inc. stock logo
DCGO
DocGo
3.80%
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
13.50%
Exagen Inc. stock logo
XGN
Exagen
12.60%
CompanyEmployeesShares OutstandingFree FloatOptionable
Agape ATP Corporation stock logo
ATPC
Agape ATP
4050.01 million45.17 millionNot Optionable
DocGo Inc. stock logo
DCGO
DocGo
4,40797.81 million94.09 millionOptionable
Sera Prognostics, Inc. stock logo
SERA
Sera Prognostics
12037.67 million32.59 millionOptionable
Exagen Inc. stock logo
XGN
Exagen
22022.00 million19.23 millionOptionable

Recent News About These Companies

Palumbo Wealth Management LLC Trims Position in Exagen Inc. $XGN
What is B. Riley's Forecast for Exagen Q3 Earnings?
Exagen (NASDAQ:XGN) Now Covered by B. Riley
Exagen initiated with a Buy at B. Riley
Beyond The Numbers: 4 Analysts Discuss Exagen Stock
Exagen Inc. (NASDAQ:XGN) Short Interest Update
BTIG Sticks to Their Buy Rating for Exagen (XGN)
Exagen (XGN) Receives a Buy from Craig-Hallum
Exagen Inc. Reports Record Revenue Amidst Growth Challenges
Keybanc Upgrades Exagen (XGN)
Exagen Q2 Revenue Jumps 14 Percent

New MarketBeat Followers Over Time

Media Sentiment Over Time

Agape ATP stock logo

Agape ATP NASDAQ:ATPC

$1.28 -0.01 (-0.39%)
As of 11:07 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Agape ATP Corporation, an investment holding company, supplies health and wellness products and health solution advisory services in Malaysia. It offers four series of programs that consist of various services and products under the ATP Zeta Health Program, ÉNERGÉTIQUE, BEAUNIQUE, and E.A.T.S. names. The company's products include ATP1s Survivor Select that contains various essential nutrients required by the human body to maintain normal metabolism; ATP3 Ionized Cal-Mag, a calcium and magnesium minerals supplement; ATP4 Omega Blend, an oil blend that provides a bio-effective balance of essential fatty acids, omega 3, and omega 6; ATP5 BetaMaxx, a natural immune enhancer; AGN-Vege Fruit Fiber, a nutrition-based formulation for intestines and stomach; AGP1-Iron to improve iron deficiency anemia; and YFA-Young Formula, an anti-aging and youthful maintenance supplement. It also provides BEAUNIQUE brand products comprising Mito+, an antioxidant drink for cellular, immune, metabolic, brain, and skin health; and Trim+, which inhibits the activities of carbohydrates digestive enzymes that result in a reduction of the breakdown and absorption of sugars. In addition, the company offers energy masks, including N°1 Med-Hydration, N°2 Med-Whitening, and N°3 Med-Firming, as well as hyaluronic acid serum and mousse facial cleanser under ÉNERGÉTIQUE brand; and soy protein isolate powder, and an antioxidant under Livo5 brand name. Further, it sells health and wellness products; and promotes wellness and wellbeing lifestyle through online editorials, programs, events, and campaigns, as well as provides health therapies. The company was incorporated in 2016 and is headquartered in Kuala Lumpur, Malaysia.

DocGo stock logo

DocGo NASDAQ:DCGO

$1.38 -0.01 (-0.36%)
As of 11:18 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

DocGo Inc. provides mobile health and medical transportation services for various health care providers in the United States and the United Kingdom. The company's transportation services include emergency response services; and non-emergency transport services comprise ambulance and wheelchair transportation services. It also offers mobile health services through its platform that are performed at home, offices, and other locations; event services, which include on-site healthcare support at sporting events and concerts; and total care management solutions comprising healthcare services and ancillary services, such as shelter. DocGo Inc. was founded in 2015 and is headquartered in New York, New York.

Sera Prognostics stock logo

Sera Prognostics NASDAQ:SERA

$3.00 +0.06 (+1.86%)
As of 11:14 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preterm birth, preeclampsia, molecular time-to-birth, predictive analytics, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.

Exagen stock logo

Exagen NASDAQ:XGN

$10.94 +0.37 (+3.45%)
As of 11:18 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.